نتائج البحث - Maria Dębiec‐Rychter

تنقيح النتائج
  1. 1
    Cellular angiofibroma: another mesenchymal tumour with 13q14 involvement, suggesting a link with spindle cell lipoma and (extra)mammary myofibroblastoma

    Cellular angiofibroma: another mesenchymal tumour with 13q14 involvement, suggesting a link with spindle cell lipoma and (extra)mammary myofibroblastoma حسب Francesca Maggiani, Maria Dębiec‐Rychter, M. Vanbockrijck, Raf Sciot

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases

    Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases حسب Els Lierman, Sanne Smits, Jan Cools, Barbara Dewaele, Maria Dębiec‐Rychter, Peter Vandenberghe

    منشور في 2012
    احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model

    Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model حسب Stefan M. Willems, Maria Dębiec‐Rychter, Károly Szuhai, Pancras C.W. Hogendoorn, Raf Sciot

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    A phase II trial with rosiglitazone in liposarcoma patients

    A phase II trial with rosiglitazone in liposarcoma patients حسب Guy Debrock, V Vanhentenrijk, Raf Sciot, Maria Dębiec‐Rychter, Raymond Oyen, A. Van Oosterom

    منشور في 2003
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors

    Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors حسب Michael C. Heinrich, Diana Griffith, Arin McKinley, Janice Patterson, Ajia Presnell, Abhijit Ramachandran, Maria Dębiec‐Rychter

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site

    Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site حسب Bartosz Wasąg, Maria Dębiec‐Rychter, Patrick Pauwels, Michel Stul, Hilde Vranckx, A. van Oosterom, Anne Hagemeijer, Raf Sciot

    منشور في 2004
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate – The impact of fibrosarcomatous transformation

    Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate – The impact of fibrosarcomatous transformation حسب Piotr Rutkowski, Anna Klimczak, Iwona Ługowska, Beata Jagielska, Michał Wągrodzki, Maria Dębiec‐Rychter, Barbara Pieńkowska‐Grela, Tomasz Świtaj

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Recurrent<i>MALAT1-GLI1</i>oncogenic fusion and<i>GLI1</i>up-regulation define a subset of plexiform fibromyxoma

    Recurrent<i>MALAT1-GLI1</i>oncogenic fusion and<i>GLI1</i>up-regulation define a subset of plexiform fibromyxoma حسب Lien Spans, Christopher D.�M. Fletcher, Cristina R. Antonescu, Alexandre Rouquette, Jean‐Michel Coindre, Raf Sciot, Maria Dębiec‐Rychter

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous <i>KIT</i> Mutations

    The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous <i>KIT</i> Mutations حسب Giuseppe Floris, Raf Sciot, Agnieszka Woźniak, Thomas Van Looy, Jasmien Wellens, Gavino Faa, Emmanuel Normant, Maria Dębiec‐Rychter, Patrick Schöffski

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

    Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability حسب Nicolas Widmer, Laurent A. Décosterd, Serge Leyvraz, Michel A. Duchosal, Anne Rosselet, Maria Dębiec‐Rychter, Chantal Csajka, J Biollaz, Thierry Buclin

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation

    Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation حسب Barbara Dewaele, Bartosz Wasąg, Jan Cools, Raf Sciot, Hans Prenen, Peter Vandenberghe, Agnieszka Woźniak, Patrick Schöffski, Peter Marynen, Maria Dębiec‐Rychter

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Clustering of deletions on chromosome 13 in benign and low‐malignant lipomatous tumors

    Clustering of deletions on chromosome 13 in benign and low‐malignant lipomatous tumors حسب Anna Dahlén, Maria Dȩbiec‐Rychter, Florence Pédeutour, Henryk A. Domanski, Mattias Höglund, Henrik C. F. Bauer, Anders Rydholm, Raf Sciot, Nils Mandahl, Fredrik Mertens

    منشور في 2002
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy

    Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy حسب Thomas Van Looy, Agnieszka Woźniak, Giuseppe Floris, Raf Sciot, Haifu Li, Jasmien Wellens, Ulla Vanleeuw, Jonathan A. Fletcher, Paul W. Manley, Maria Dębiec‐Rychter, Patrick Schöffski

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Molecular genetic characterization of the <i>EWS/ATF1</i> fusion gene in clear cell sarcoma of tendons and aponeuroses

    Molecular genetic characterization of the <i>EWS/ATF1</i> fusion gene in clear cell sarcoma of tendons and aponeuroses حسب Ioannis Panagopoulos, Fredrik Mertens, Maria Dębiec‐Rychter, Margareth Isaksson, Janusz Limon, Iwona Kardaś, Henryk A. Domanski, Raf Sciot, Danuta Perek, Sead Crnalic, Olle Larsson, Nils Mandahl

    منشور في 2002
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors

    p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors حسب Joern Henze, Thomas Mühlenberg, Susanne Simon, Florian Grabellus, Brian P. Rubin, G. Taeger, Martin Schüler, Juergen Treckmann, Maria Dębiec‐Rychter, Takahiro Taguchi, Jonathan A. Fletcher, Sebastian Bauer

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets

    In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets حسب Elsa Arbajian, Florian Puls, Cristina R. Antonescu, Fernanda Amary, Raf Sciot, Maria Dębiec‐Rychter, Vaiyapuri P. Sumathi, Marcus Järås, Linda Magnusson, Jenny Nilsson, Jakob Hofvander, Fredrik Mertens

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

    Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants حسب Maria Dębiec‐Rychter, Jan Cools, Herlinde Dumez, Raf Sciot, Michel Stul, Nicole Mentens, Hilde Vranckx, Bartosz Wasąg, Hans Prenen, Johannes Roesel, Anne Hagemeijer, A. van Oosterom, Peter Marynen

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal

    A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal حسب Giuseppe Floris, Agnieszka Woźniak, Raf Sciot, Haifu Li, Lori S. Friedman, Thomas Van Looy, Jasmien Wellens, Peter Vermaelen, Christophe M. Deroose, Jonathan A. Fletcher, Maria Dębiec‐Rychter, Patrick Schöffski

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors

    Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors حسب Yemarshet K. Gebreyohannes, Agnieszka Woźniak, Madalina-Elena Zhai, Jasmien Wellens, Jasmien Cornillie, Ulla Vanleeuw, Erica Evans, Alexandra K. Gardino, Christoph Lengauer, Maria Dębiec‐Rychter, Raf Sciot, Patrick Schöffski

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases

    Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases حسب David Suster, Michael Michal, Huiya Huang, Shira Ronen, Stephanie Springborn, Maria Dȩbiec‐Rychter, Steven D. Billings, John R. Goldblum, Brian P. Rubin, Michal Michal, Saul Suster, Alexander C. Mackinnon

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: